Adenosine deaminase
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='2pgf' size='350' side='right' caption='Structure of adenosine deaminase complex with Zn+2 (grey), acetonitrile and adenosine (stick model) (PDB entry [[2pgf]])' scene=''> | <StructureSection load='2pgf' size='350' side='right' caption='Structure of adenosine deaminase complex with Zn+2 (grey), acetonitrile and adenosine (stick model) (PDB entry [[2pgf]])' scene=''> | ||
| - | '''Adenosine deaminase''' (ADA) deaminates adenosine and deoxyadenosine into inosine or deoxyinosine. ADA is part of the purine metabolism. In humans ADA is involved in the development and maintenance of the immune system. ADA deficiency is the cause of severe combined immunodeficiency (SCID). SCID was the first disorder to be treated by gene therapy. There are 2 isoforms of ADA: ADA1 and ADA2. ADA contains Zn+2 ion in its active site. | + | == Function == |
| + | |||
| + | '''Adenosine deaminase''' (ADA) deaminates adenosine and deoxyadenosine into inosine or deoxyinosine. ADA is part of the purine metabolism. In humans ADA is involved in the development and maintenance of the immune system. ADA binds dipeptidyl peptidase IV. The complex acts as a positive regulator of T-cell coactivation and regulates lymphocytes-epithelial adhesion. | ||
| + | |||
| + | == Disease == | ||
| + | |||
| + | ADA deficiency is the cause of severe combined immunodeficiency (SCID). SCID was the first disorder to be treated by gene therapy. | ||
| + | |||
| + | == Relevance == | ||
| + | |||
| + | ADA is used in testing for the presence of tuberculosis as its level is increased in TB patients. | ||
| + | |||
| + | == Structural highlights == | ||
| + | |||
| + | There are 2 isoforms of ADA: ADA1 and ADA2. ADA contains Zn+2 ion in its active site. | ||
</StructureSection> | </StructureSection> | ||
Revision as of 12:15, 27 October 2015
| |||||||||||
3D Structures of adenosine deaminase
Updated on 27-October-2015
